The future of human health will be defined by technologies that accelerate the world's access to more effective medicines.
Human cells are a cornerstone of fundamental disease research, drug discovery, and clinical translation. Yet, despite decades of research into iPSCs, emerging cures for some of the world’s most pervasive diseases have been bottlenecked by a lack of access to standardised, easy to use and readily accessible human cells.
We built ioCells to solve this challenge.
Developed on our platform, and powered by opti-ox technology, ioCells are human cells deterministically programmed from iPSCs consistently, at scale. With ioCells, scientists no longer need to battle with variance, unreliability, physiological irrelevance and long experimental timelines. Instead, scientists can finally focus on the next great advances in human health.
ioCells are for research use only.
ioWild Type Cells
ioWild Type Cells are defined, easy-to-use, functional iPSC-derived human cells from a healthy donor background that are ready for fundamental research and drug discovery experimentation within days.
ioDisease Model Cells
ioDisease Model Cells are ioWild Type Cells engineered to contain disease-relevant mutations. ioDisease Model Cells and ioWild Type Cells form an isogenic pair allowing scientists to make true comparisons.
CRISPR-Ready ioCells
CRISPR-Ready ioCells are human iPSC-derived cells constitutively expressing Cas9 nuclease for rapid gene knockout generation.
ioTracker Cells
ioTracker Cells are human iPSC-derived cells constitutively expressing a fluorescent protein for easy visualisation, tracking, and isolation of human cells in live-cell imaging assays.
Consistent
Our platform ensures consistency between every batch of cells, overcoming the challenge of data reproducibility.
Cost-effective
ioCells generate quality data at industry leading seeding densities. You can do more with every vial as every well saves you money.
Defined
Every ioCell has its identity characterised by ICC, RT-qPCR and RNA-Seq at minimum.
Easy-to-use
ioCells are delivered cryopreserved and require a simple protocol using an open-source medium to get started.
Quick
Deterministically programmed cells mature rapidly, meaning cells are ready for experimentation and data gathering within days post-revival.
Scalable
With opti-ox technology we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.
Dr Marijn Vlaming
Head of Biology - Beerse & Leiden | Charles River
Dr Mariangela Iovino
Senior Group Leader | Biology Discovery | Charles River
Rodney A. Bowling Jr, PhD
Co-Founder & Chief Scientific Officer | Everlum Bio
Every ioCell is powered by opti-ox.
Using opti-ox, populations of stem cells are precisely and consistently programmed into a chosen cell identity. Each vial of ioCells contains a defined and highly characterised population of iPSC-derived human cells that are ready for quality data production in a matter of days. Their high lot-to-lot consistency provides a reliable cell model that enables scientists to conduct repeatable and scalable experiments in drug discovery and disease research.
Dr Ben Bar-Sadeh | Senior Scientist | Anima Biotech
Human Cell Forum 2025
Session 3 | Making complex human biology compatible with modern drug discovery workflows
Dr Sara Martin | Scientist | Axxam
Human Cell Forum 2025
Session 3 | Making complex human biology compatible with modern drug discovery workflows
Dr Martina Esposito Soccoio | Senior Research Associate | AviadoBio
Human Cell Forum 2025
Session 3 | Making complex human biology compatible with modern drug discovery workflows
Sejla Salic-Hainzl | Vice President of R&D | bit.bio discovery
Human Cell Forum 2025
Session 2 | bit.bio insider: Tools, tips, and what’s coming next
Dr Gianmarco Mastrogiovanni | Principal Scientist - Cell Type Development | bit.bio
Human Cell Forum 2025
Session 2 | bit.bio insider: Tools, tips, and what’s coming next
Euan Yates | Scientist | bit.bio
Human Cell Forum 2025
Session 2 | bit.bio insider: Tools, tips, and what’s coming next
Luke Foulser | Field Applications Scientist | bit.bio
Human Cell Forum 2025
Session 2 | bit.bio insider: Tools, tips, and what’s coming next
Dr Grace Cooper | Senior Scientist | bit.bio
Human Cell Forum 2025
Session 1 Track 2 | From cells to systems: Building human iPSC-derived models of pain, neuromuscular junctions, and glial dynamics
Jeremy Krohn | PhD Candidate | DZNE / Charité University of Medicine
Human Cell Forum 2025
Session 1 Track 2 | From cells to systems: Building human iPSC-derived models of pain, neuromuscular junctions, and glial dynamics
Dr Ryan Jones | Research Associate | Cardiff University
Human Cell Forum 2025
Session 1 Track 2 | From cells to systems: Building human iPSC-derived models of pain, neuromuscular junctions, and glial dynamics
Dr Elizabeth Di Lullo | Associate Scientific Director | BrainEver
Human Cell Forum 2025
Session 1 Track 1 | Modelling neurodegeneration in vitro with human iPSC-derived cells
Dr Irantzu Perez Ruiz | Study Director | Scantox Neuro
Human Cell Forum 2025
Session 1 Track 1 | Modelling neurodegeneration in vitro with human iPSC-derived cells
Dr Emmanouil Metzakopian | Visiting researcher | University of Cambridge
Human Cell Forum 2025
Session 1 Track 1 | Modelling neurodegeneration in vitro with human iPSC-derived cells
Date | 14th October 2025
Time | 8am PDT | 11am EDT | 4pm BST | 5pm CEST
Fuad Mosis, PhD | Technical Support Specialist | bit.bio
Thomas Moreau, PhD | VP Cell Programming Research | bit.bio
Ann Byrne, MSc | Regional Sales Manager, APAC | bit.bio
Gianmarco Mastrogiovanni, PhD | Principle Scientist - Cell Type Development | bit.bio
Jack Gowen, MSc | Scientist, QC and GMP, Analytical Development | bit.bio
Charlotte Durham, BSc | Operational Quality Manager | bit.bio
Luke Foulser, MSc | Field Applications Scientist | bit.bio
Austin Passaro, PhD | Global Product Manager MEA | Axion Biosystems
Marius Wernig, Professor | Departments of Pathology and Chemical, and Systems Biology and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine | Stanford University
Samantha Morris, PhD | Principle Investigator | Brigham and Women’s Hospital and Harvard Medical School, Department of Systems Biology
Thomas Moreau, PhD | Vice President of Cell Programming Research | bit.bio
Ben Bar-Sadeh, PhD | Senior Scientist | Anima Biotech
Tom Brown | Senior Product Manager | bit.bio
Sebastian Fiedler, PhD | Applications Marketing Manager | bit.bio
Malika Bsibsi, PhD | Research Leader Neuroscience | Charles River Laboratories
Austin Passaro, PhD | Global Product Manager MEA | Axion Biosystems
Cicely Schramm, PhD | Head of Biology Imaging | Sartorius
Antonella Santuccione Chadha, MD | Founder and CEO | Women’s Brain Foundation
Melanie Einsiedler, PhD | Scientific Contributor | Women’s Brain Foundation
Rebecca Northeast, PhD | Senior Product Manager | bit.bio
Stephen Ferguson, PhD | Investigator, Mechanistic Toxicology | Division of Translational Toxicology (DTT) | National Institute of Environmental Health Sciences
Tom Brown | Senior Product Manager | bit.bio
Professor Luke Gilbert | Associate Professor | University of California San Francisco
Sejla Salic-Hainzl | Vice President of Research and Development | bit.bio
Bernard, et al
bit.bio
2024
Dr Brian Gill, MD | Assistant Professor of Neurological Surgery| Columbia University Irving Medical Center
Dr Tony Oosterveen | Principal Scientist and CNS Lead, Neurobiology | bit.bio
Luke Foulser | Scientist | bit.bio
Tom Brown | Senior Product Manager | bit.bio
Marcos Herrera Vaquero, PhD | Senior Scientist | bit.bioVaquero, et al
bit.bio
2023
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Dr Marieke Aarts | Principal Scientist | Bi/ond
Amanda Turner | Senior Product Manager | bit.bio
Dr Mitchell Han
Bi/ond
2023
V2
bit.bio
2023
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Prof Roger Pedersen | Adjunct Professor and Senior Research Scientist at Stanford University
Dr Thomas Moreau | Director of Cell Biology Research | bit.bio
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Rodney A. Bowling Jr., Ph.D. | Chief Scientific Officer | Everlum Bio
Malathi Raman Ph.D. | Senior Product Manager | bit.bio
Oosterveen, et al
bit.bio
2022
Ritsma, et al
Charles River Laboratories & bit.bio
2022
Raman, et al
bit.bio
2022
Dr Matthias Pawlowski | Head, Dementia-Sensitive Hospital | University of Münster
Dr Malathi Raman | Senior Product Manager | bit.bio
bit.bio
Dr Emma V Jones | Senior Scientist | Medicines Discovery Catapult
Dr Tony Oosterveen | Senior Scientist | bit.bio
Dr Deepak Srivastava | King’s College London
Dr Mariangela Iovino | Group Leader | Charles River
Dr Tony Oosterveen | Senior Scientist | bit.bio
Dr Will Bernard | Director of Cell Type Development | bit.bio
Dr Luke Flatt | Senior Scientist | Charles River Laboratories
Dr Will Bernard | Senior Scientist | bit.bio
Dr Marijn Vlaming | Head of Biology, et al.
Charles River & bit.bio
Dr Marijn Vlaming | Head of Biology
Charles River
Dr Alex Davenport | Senior Scientist | bit.bio
Talk at ELRIG Cell & Gene Therapy
2021
Kam Dhaliwal | SVP Strategic Alliances | bit.bio
Talk at ELRIG CRISPR in Drug Discovery
Kings College London & bit.bio
Panel discussion at Oxford Global Discovery UK
Lachize, et al
Courtesy of Charles River Laboratories
2020
Kam Dhaliwal | SVP Strategic Alliances | bit.bio
Dr Thomas Moreau | Head of Research | bit.bio
Talk at ELRIG Drug Discovery Digital
bit.bio (chair) | AstraZeneca | PhoreMost Ltd | Aelian Biotechnology GmbH | Charles River
Panel discussion at ELRIG Drug Discovery Digital
Dr Shushant Jain | Group Leader In Vitro Biology | Charles River
Interview at SLAS
Prof Hagan Bayley | University of Oxford
Dr Mark Kotter | Founder and CEO | bit.bio